User profiles for Simone Saibeni

Simone Saibeni

Gastroenterology Unit, Rho Hospital, ASST Rhodense, Italy
Verified email at asst-rhodense.it
Cited by 6171

Inflammation and Coagulation in Inflammatory Bowel Disease: The Clot Thickens: CME

S Danese, A Papa, S Saibeni, A Repici… - Official journal of the …, 2007 - journals.lww.com
Inflammation and coagulation play crucial roles in the pathogenesis of multiple chronic
inflammatory disorders. Growing evidence highlights a tight mutual network in which inflammation…

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre …

…, R Rocca, J Romatowski, G Rydzewska, S Saibeni… - The Lancet, 2022 - thelancet.com
Background Active-comparator trials are important to inform patient and physician choice.
We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or …

Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study

C Bezzio, S Saibeni, A Variola, M Allocca, A Massari… - Gut, 2020 - gut.bmj.com
Objectives COVID-19 has rapidly become a major health emergency worldwide. Patients
with IBD are at increased risk of infection, especially when they have active disease and are …

Low vitamin B6 plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants

S Saibeni, M Cattaneo, M Vecchi… - Official journal of the …, 2003 - journals.lww.com
OBJECTIVES: Individuals with inflammatory bowel disease (IBD) are at increased risk for
thrombosis and vitamin deficiencies. Low plasma levels of vitamin B 6 are an independent risk …

Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study

G Meucci, R Fasoli, S Saibeni, D Valpiani… - Inflammatory bowel …, 2012 - academic.oup.com
Background It has been recommended that the treatment of active ulcerative colitis (UC)
should be continued until complete healing of endoscopic lesions. However, the evidence …

Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification …

AV Marzano, RS Ishak, S Saibeni, C Crosti… - Clinical reviews in …, 2013 - Springer
Pyoderma gangrenosum (PG) and Sweet’s syndrome (SS) are skin diseases usually
presenting with recurrent ulcers and erythematous plaques, respectively. The accumulation of …

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial

…, K Patel, P Desreumaux, S Saibeni… - The Lancet …, 2022 - thelancet.com
Background A treat-to-target strategy, in which strictly defined treatment targets facilitate
decision making in clinical practice, is advocated as an optimised management approach for …

ECCO guidelines on inflammatory bowel disease and malignancies

…, T Molnár, NM Noor, R Rao, S Saibeni… - Journal of Crohn's …, 2023 - academic.oup.com
This guideline is the second European Crohn’s and Colitis Organisation [ECCO] evidence-based
consensus on inflammatory bowel disease [IBD] and malignancy, and is an update on …

Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice

…, M Cazzaniga, M Merli, G Spinzi, S Saibeni… - Journal of …, 2011 - Elsevier
BACKGROUND & AIMS: Hepatorenal syndrome (HRS) is a severe complication of cirrhosis
with ascites. The International Ascites Club recommended strict diagnostic criteria and …

Clinical and laboratory aspects of Ro/SSA-52 autoantibodies

…, A Cereda, G Guercilena, S Bollani, S Saibeni… - Autoimmunity …, 2011 - Elsevier
Anti-Ro/SSA antibodies, which were described for the first time in systemic lupus erythematosus
(SLE) and Sjögren's syndrome (SS), are the most prevalent extractable nuclear antigen (…